In Brief: Cambridge Biotech
This article was originally published in The Gray Sheet
Executive Summary
Cambridge Biotech: Enters agreement to sell its enterics (intestinal disease) and human Lyme EIA diagnostic businesses to Carter-Wallace for $4.5 mil. cash. Carter-Wallace gains tests for rotavirus (Rotaclone), adenovirus (Adenoclone and Adenoclone 40/41), and C. difficle (Cytoclone), as well as a test for Lyme Disease. The tests will be sold by Carter-Wallace's Wampole Laboratories division and initially will be manufactured at Cambridge Biotech's Worcester, Massachusetts facility under a six month contract. The deal completes a restructuring plan Cambridge Biotech filed with U.S. bankruptcy court in April. Under the plan, Cambridge Biotech will focus its business -- to be renamed Aquila Biopharmaceuticals -- on "developing and commercializing therapeutic and prophylactic vaccines for infectious diseases." The firm recently announced the sale of its retroviral diagnostics business to bioMerieux Vitek for $6.5 mil. cash...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.